Positive Phase III Results Emerge for Remibrutinib in Chronic Spontaneous Urticaria Treatment Medha Baranwal25 Jun 2024 8:00 PM ISTUSA: In a significant development for patients suffering from chronic spontaneous urticaria (CSU), Novartis has released promising Phase III trial...
CDSCO Panel grants Novartis Protocol Amendment Proposal to study Remibrutinib in Chronic Spontaneous Urticaria Dr. Divya Colin21 May 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
CDSCO Panel grants Novartis Protocol Amendment proposal for Remibrutinib study in Relapsing Multiple Sclerosis Dr. Divya Colin5 Feb 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis Gets CDSCO Panel Nod to study Remibrutinib to treat chronic spontaneous urticaria Dr. Divya Colin8 Dec 2023 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis raises sales growth target to 5 percent a year through 2027 Ruchika Sharma28 Nov 2023 3:30 PM ISTFrankfurt: Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of...
Remibrutinib new option beyond antihistamines for managing chronic spontaneous urticaria Aditi23 Nov 2023 2:30 PM ISTRemibrutinib (LOU064) is a highly selective Bruton's tyrosine kinase inhibitor (BTKi). It has demonstrated the ability to effectively manage symptoms...
Remibrutinib improves outcomes in Chronic Spontaneous Urticaria Patients Jacinthlyn Sylvia31 Oct 2023 2:30 AM ISTPatients with chronic spontaneous urticaria (CSU) who have found little relief with existing treatments, a novel drug called Remibrutinib (LOU064) has...
Remibrutinib could be new effective and fast-acting oral treatment option for chronic spontaneous urticaria: Phase 3 trials Dr. Kamal Kant Kohli12 Aug 2023 11:15 AM ISTSwitzerland: The phase 3 trials REMIX-1 and REMIX-2 have yielded positive top-line results, as announced by Novartis. Trials assessed remibrutinib 25...
Submit complete safety data: CDSCO panel tells Novartis on Remibrutinib Dr. Divya Colin23 April 2023 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the drug maker...
Remibrutinib oral therapy effective against Sjogren's syndrome Jacinthlyn Sylvia23 Nov 2022 8:00 PM ISTOver the course of 24 weeks, remibrutinib was well tolerated by Sjögren's syndrome (SS) patients and had a favorable safety profile. The findings were...
